Drugs in development · updated 13 November 2026
CX11: clinical trials and development status
Other names and codes: VCT220
As of 13 November 2026 CX11 is in 4 active clinical trials (recruiting or ongoing, phases I–III) for 5 diseases. The most advanced phase is II.
Authorisation
- EU no (EMA)
- Italy not in the AIFA register
- Germany not available
- US no (FDA)
Sources: EMA, AIFA register (open data), FDA. For Germany only the EU centralised authorisation is shown: the national BfArM register is not one of our sources.
Map of sites in Europe with recruitment status, every trial and an email when something changes. Full access free until 31 March 2027, no card needed.
Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Type 2 diabetes | II | 2 | NCT07340320 |
| Arterial hypertension | II | 1 | NCT07360275 |
| Hypoglycemia | II | 1 | NCT07340320 |
| Obesity | I | 1 | NCT07652047 |
| Overweight | I | 1 | NCT07652047 |
Sites in Europe
14 sites of the active trials in one European country, 0 recruiting.
- Poland14
Sites declared by the sponsors on ClinicalTrials.gov; region worked out by Phuturdex from the geographic point. The list of sites with city and recruitment status is in the app. See the sites →
Everything on CX11
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 13 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, refers to the United States and is a Phuturdex calculation described on the Method page, not official data: the drug may already be marketed in other countries.